Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug trial for MET-Positive lung cancer halted early

NCT ID NCT05513703

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called telisotuzumab vedotin for people with a specific type of advanced lung cancer (non-squamous non-small cell lung cancer) that has a MET gene change. The goal was to see if the drug could shrink tumors. The trial was stopped early and enrolled only 9 participants instead of the planned 70.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

9 people

The number who actually took part.

Started

Nov 2022

Finished

Oct 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Must have MET amplification in tumor tissue as determined by the Sponsor-designated central laboratory MET FISH Assay or in plasma and/or tissue by a Sponsor-approved assay. * Must have histologically documented non-squamous adenocarcinoma non-small cell lung cancer (NSCLC) that is locally advanced or metastatic. * Must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. * Must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Participant may have received prior adjuvant/neoadjuvant systemic chemotherapy and/or radiation and/or immunotherapy provided that the subject has not progressed on or within 6 months of completing the regimen and it was completed \>= 6 months before subject's first dose of study drug. * Metastases to the central nervous system (CNS) are eligible only after definitive therapy is provided as noted in the protocol. * History of radiation pneumonitis in the radiation field (fibrosis) is permitted. Exclusion Criteria: * Alterations in EGFR, ALK, ROS1, or BRAF that predict sensitivity to available targeted therapy. Participants with other alterations that are candidates for available targeted therapy. * Prior systemic therapy for locally advanced/metastatic NSCLC. Of note, limited treatment with no more than 1 cycle of chemotherapy is allowed prior to receiving the first dose of study drug provided there is no evidence of progression. * Have a history of other malignancies except those noted in the protocol. * Have a history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. * Received prior c-Met-targeted antibodies. * Have NSCLC that is eligible for treatment with curative intent. * Have unresolved adverse events (AEs) \>= Grade 2 from prior anticancer therapy, except for alopecia or anemia. * Have had major surgery within 21 days prior to the first dose of telisotuzumab vedotin. * Have clinically significant condition(s) as noted in the protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer

Contacts and locations

Locations

  • Asklepios Fachkliniken Muenchen-Gauting /ID# 248082

    Gauting, 82131, Germany

  • CHU Lille - Hôpital Albert Calmette /ID# 246263

    Lille, Hauts-de-France, 59037, France

  • Cancer and Blood Speciality Clinic - Los Alamitos /ID# 251671

    Los Alamitos, California, 90720-3309, United States

  • Centre Jean Perrin /ID# 246268

    Clermont-Ferrand, 63011, France

  • Chungbuk National University Hospital /ID# 248405

    Cheongju-si, North Chungcheong, 28644, South Korea

  • Duplicate_Fondazione IRCCS San Gerardo dei Tintori /ID# 247584

    Monza, Monza E Brianza, 20900, Italy

  • Duplicate_National Hospital Organization Kyushu Cancer Center /ID# 250714

    Fukuoka, Fukuoka, 811-1395, Japan

  • Hadassah Medical Center-Hebrew University /ID# 243298

    Jerusalem, Jerusalem, 91120, Israel

  • Hokkaido University Hospital /ID# 250316

    Sapporo, Hokkaido, 060-8648, Japan

  • Hospices Civils de Lyon (HCL) - Hopital Louis Pradel /ID# 246267

    Bron, Rhone, 69500, France

  • IRCCS Istituti Fisioterapici Ospitalieri-Istituto Nazionale Tumori Regina Elena /ID# 247585

    Rome, 00144, Italy

  • Istituto di Candiolo Fondazione del Piemonte per l'Oncologia IRCCS /ID# 248329

    Candiolo, Torino, 10060, Italy

  • Kaohsiung Chang Gung Memorial Hospital /ID# 248143

    Kaohsiung City, Kaohsiung, 833, Taiwan

  • Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 248144

    Kaohsiung City, 807, Taiwan

  • Keimyung University Dongsan Hospital /ID# 247371

    Daegu, Gyeongsangbuk-do, 42601, South Korea

  • Linkou Chang Gung Memorial Hospital /ID# 248145

    Taoyuan City, 333, Taiwan

  • Meir Medical Center /ID# 243208

    Kfar Saba, Central District, 4428164, Israel

  • Monash Health - Monash Medical Centre /ID# 247679

    Clayton, Victoria, 3168, Australia

  • National Cancer Center Hospital /ID# 250319

    Chuo-ku, Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East /ID# 250317

    Kashiwa-shi, Chiba, 277-8577, Japan

  • National Cheng Kung University Hospital /ID# 248142

    Tainan, 704, Taiwan

  • Osaka International Cancer Institute /ID# 251507

    Osaka, Osaka, 541-8567, Japan

  • Pusan National University Yangsan Hospital /ID# 248489

    Yangsan, Gyeongsangnam-do, 50612, South Korea

  • Rabin Medical Center /ID# 248631

    Petah Tikva, 4941492, Israel

  • Rambam Health Care Campus /ID# 246781

    Haifa, H_efa, 3109601, Israel

  • Samsung Medical Center /ID# 248407

    Seoul, Seoul Teugbyeolsi, 06351, South Korea

  • Shizuoka Cancer Center /ID# 251752

    Sunto-gun, Shizuoka, 411-8777, Japan

  • The Chaim Sheba Medical Center /ID# 243207

    Ramat Gan, Tel Aviv, 5265601, Israel

  • Valley Medical Center /ID# 251880

    Renton, Washington, 98055-5738, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.